Claims for Patent: 6,369,294

Summary for Patent: 6,369,294

Title:	Methods comprising apoptosis inhibitors for the generation of transgenic pigs
Abstract:	Disclosed are methods for the isolation of primordial germ cells, culturing these cells to produce primordial germ cell-derived cell lines, methods for transforming both the primordial germ cells and the cultured cell lines, and using these transformed cells and cell lines to generate transgenic animals. The efficiency at which transgenic animals are generated by the present invention is greatly increased, thereby allowing the use of homologous recombination in producing transgenic non-rodent animal species.
Inventor(s):	Piedrahita; Jorge A. (College Station, TX), Bazer; Fuller W. (College Station, TX)
Assignee:	Texas A&M University System (College Station, TX)
Application Number:	09/819,964
Patent Claims:	1. A method of growing porcine primordial germ cells, comprising growing a cell culture comprising porcine primordial germ cells from an embryo of a pig on feeder cells for a time sufficient to obtain undifferentiated porcine primordial germ cells, said feeder cells at a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 cells/cm.sup.2, in a culture medium comprising an effective amount of basic fibroblast growth factor and an apoptosis inhibitor. 2. The method of claim 1, wherein said feeder cells are STO feeder cells. 3. The method of claim 1, wherein said culture medium comprises basic fibroblast growth factor at a concentration of between about 5 ng/ml and about 100 .mu.g/ml. 4. The method of claim 1, wherein said apoptosis inhibitor is a serine protease apoptosis inhibitor. 5. The method of claim 1, wherein said apoptosis inhibitor is an antioxidant apoptosis inhibitor. 6. The method of claim 1, wherein said apoptosis inhibitor is selected from the group consisting of bcl-2, Bcl-x1, Mcl-1, Bak, A1, A20, TNF-.alpha., nerve growth factor, epidermal growth factor, insulin-like growth factor-I, insulin-like growth factor-I receptor, 3 -aminobenzamide, aphidocolin, L-ascorbic acid, cataiase, follicle stimulating hormone, vasoactive intestinal peptide, cyclic GMP, hCG, interleukin-1.beta., superoxide dismutase, aurintricarboxylic acid, BAPTA/AM, caffeine, calpain inhibitor I, calpain inhibitor II, leupeptin, N-ethyl maleimaide, cyclosporin A, acetyl-leucyl-leucyl-normethional, 3,4-dichloroisocoumarin, diisopropylfluorophosphate, phenylmethylsulfonyl fluoride, tetrodotoxin, nimodipine, verapamil, flunarizine, R56865, forskolin, genistein, herbimycin A, interleukin-6, calyculin A, okadaic acid, calyculin A, phorbol-12-myristate-13-acetate, 1-Pyrrolidinecarbodithioic acid, nifedipine, nisoldipine, aurintricarboxylic acid, spermine, thioredoxin, N.sup..alpha. -Tosyl-L-Phe chloromethyl ketone and N.sup..alpha. -Tosyl-L-Lys chloromethyl ketone. 7. The method of claim 6, wherein said apoptosis inhibitor is N-Acetyl-L-cysteine. 8. The method of claim 1, wherein said culture medium further comprises an effective amount of uteroferrin. 9. The method of claim 1, wherein said culture medium further comprises an effective amount of amino acids non-essential with respect to said pig. 10. The method of claim 1, wherein said culture medium further comprises an effective amount of L-glutamine. 11. The method of claim 1, wherein said culture medium further comprises an effective amount of P-mercaptoethanol. 12. The method of claim 1, wherein the porcine primordial germ cells are maintained in an undifferentiated state for between about 2 passages and about 14 passages. 13. The method of claim 1, wherein the porcine primordial germ cells comprise at least a first selected DNA segment. 14. The method of claim 13, wherein said selected DNA segment comprises at least a first coding region encoding a selected protein. 15. A method of preparing a porcine primordial germ cell-derived cell line, comprising: (a) plating a cell culture comprising porcine primordial germ cells on feeder cells, said feeder cells at a density of between, about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 cells/cm.sup.2, in a culture medium comprising an effective amount of basic fibroblast growth factor and an apoptosis inhibitor; and (b) culturing the plated porcine primordial germ cells for a period of time effective to provide a porcine primordial germ cell-derived cell line. 16. A method of preparing porcine primordial germ cells that contain a selected DNA segment, comprising: (a) introducing said selected DNA segment into a composition comprising porcine primordial germ cells to obtain candidate porcine primordial germ cells that contain said selected DNA segment; and (b) plating said candidate porcine primordial germ cells that contain said selected DNA segment on feeder cells, said feeder cells at a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 cells/cm.sup.2, in a culture medium comprising an effective amount of basic fibroblast growth factor and an apoptosis inhibitor, to obtain said porcine primordial germ cells that contain said selected DNA segment. 17. The method of claim 16, wherein said apoptosis inhibitor is a serine protease apoptosis inhibitor. 18. The method of claim 16, wherein said apoptosis inhibitor is an antioxidant apoptosis inhibitor. 19. The method of claim 16, wherein said apoptosis inhibitor is selected from the group consisting of bcl-2, Bcl-x1, Mcl-1, Bak, A1, A20, TNF-.alpha., nerve growth factor, epidermal growth factor, insulin-like growth factor-I, insulin-like growth factor-I receptor, 3-aminobenzamide, aphidocolin, L-ascorbic acid, catalase, follicle stimulating hormone, vasoactive intestinal peptide, cyclic GMP, hCG, interleukin-1.beta., superoxide dismutase, aurintricarboxylic acid, BAPTA/AM, caffeine, calpain inhibitor I, calpain inhibitor II, leupeptin, N-ethyl maleimide, cyclosporin A, acetyl-leucyl-leucyl-normethional, 3,4-dichloroisocoumarin, diisopropylfluorophosphate, phenylmethylsulfonyl fluoride, tetrodotoxin, nimodipine, verapamil, flunarizine, R56865, forskolin, genistein, herbimycin A, interleukin-6, calyculin A, okadaic acid, calyculin A, phorbol-12-myristate-13-acetate, 1-Pyrrolidinecarbodithioic acid, nifedipine, nisoldipine, aurintricarboxylic acid, spermine, thioredoxin, N.sup..alpha. -Tosyl-L-Phe chloromethyl ketone and N.sup..alpha. -Tosyl-L-Lys chloromethyl ketone. 20. The method of claim 19, wherein said apoptosis inhibitor is N-Acetyl-L-cysteine. 21. The method of claim 16, further comprising culturing said porcine primordial germ cells that contain said selected DNA segment for between about 2 and about 14 passages. 22. The method of claim 16, wherein said selected DNA segment is introduced into said porcine primordial germ cells by electroporation, particle bombardment or viral transformation. 23. The method of claim 16, wherein said selected DNA segment comprises at least a first coding region encoding a selected protein. 24. The method of claim 23, wherein said first coding region encodes a selected marker protein. 25. The method of claim 23, wherein said first coding region encodes a protein, wherein said protein is an interleukin, collagen, interferon, blood protein, hormone, growth factor, cytokine, enzyme, receptor, binding protein, immune system protein, antigen, muscle protein or oncogene receptor. 26. The method of claim 25, wherein said first coding region encodes a protein, wherein said protein is a SREHP, GP63, actinobacillus, pleuropneumoniae, pseudomonas aeruynosa, OprF, myclin basic protein, insulin, hCD59, DAF (CD55), factor IX, urokinase, (x-antitrypsin, tissue plasminogen activator, protein C, activin, adenosine deaminase, angiotensinogen I, antithrombin III, alpha I antitrypsin, apolipoprotein A-I, apolipoprotein A-II, apolipoprotein C-I, apolipoprotein C-II, apolipoprotein C-III, apolipoprotein E, atrial natriuretic factor, chorionic gonadotropin, alpha chain, beta chain, pro (rennin) chymosin, factor B complement, complement C2, complement C3, complement C4, complement C9, corticotropin releasing factor, epidermal growth factor, c-erb B, epoxide dehydratase, erythropoietin, C1 esterase inhibitor, factor VIII, factor IX, Christmas factor, factor X, fibrinogen A alpha, gamma B beta, gastrin releasing peptide, prepro glucagon, growth hormone, RF growth hormone, somatocrinin, hemopexin, inhibin, prepro insulin, insulin-like growth factor I, insulin-like growth factor II, alpha interferon, multiple leukocyte, fibroblast beta interferon, gamma interferon, interleukin-1, T-cell interleukin-2, growth factor, interleukin-3, two forms kininogen, beta subunit leuteinizing hormone, leuteinizing hormone, releasing hormone, lymphotoxin, mast cell growth factor, beta subunit nerve growth factor, PGDF c-sis oncogene, chain A, pancreatic polypeptide, icosapeptide, parathyroid hormone, prepro plasminogen, plasminogen activator, prolactin, proopiomelanocortin, protein C, prothrombin, relaxin, prepro renin, somatostatin, prepro tachykinin, substance P, substance K, urokinase or prepro vasoactive intestinal peptide protein. 27. The method of claim 23, wherein said selected DNA segment further comprises at least a second coding region encoding a selected protein. 28. The method of claim 27, wherein said first coding region encodes a selected protein and said second coding region encodes a selected marker protein. 29. The method of claim 16, wherein said DNA segment is operatively positioned under the control of a promoter. 30. The method of claim 16, wherein said selected DNA segment is operatively positioned in reverse orientation under the control of a promoter, wherein said promoter directs the expression of an antisense product. 31. The method of claim 16, wherein said DNA segment further comprises two selected DNA regions that flank said DNA segment, thereby directing the homologous recombination of said DNA segment into genomic DNA of said porcine primordial germ cells. 32. The method of claim 31, wherein said selected DNA regions comprise porcine genomic DNA. 33. The method of claim 31, wherein said DNA segment further comprises two selected DNA sequences that flank said DNA segment, thereby directing excision of said DNA segment under appropriate conditions. 34. A method of producing a transgenic pig comprising: (a) introducing a selected DNA segment into a cell culture comprising porcine primordial germ cells to obtain candidate porcine primordial germ cells that contain said selected DNA segment; (b) plating said candidate porcine primordial germ cells that contain said selected DNA segment on feeder cells, said feeder cells at a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 cells/m.sup.2, in a culture medium comprising an effective amount of basic fibroblast growth factor and an apoptosis inhibitor, to obtain undifferentiated porcine primordial germ cells that contain said selected DNA segment; and (c) generating a transgenic pig from said undifferentiated porcine primordial germ cells that contain said selected DNA segment wherein said selected DNA segment is contained and expressed in somatic and germ cells of said transgenic pig. 35. The method of claim 34, wherein said apoptosis inhibitor is a serine protease apoptosis inhibitor. 36. The method of claim 34, wherein said apoptosis inhibitor is an antioxidant apoptosis inhibitor. 37. The method of claim 34, wherein said apoptosis inhibitor is selected from the group consisting of bcl-2, Bcl-x1, Mcl-1, Bak, A1, A20, TNF-.alpha., nerve growth factor, epidermal growth factor, insulin-like growth factor-I, insulin-like growth factor-I receptor, 3-aminobenzamide, aphidocolin, L-ascorbic acid, catalase, follicle stimulating hormone, vasoactive intestinal peptide, cyclic GMP, hCG, interleukin-1.beta., superoxide dismutase, aurintricarboxylic acid, BAPTA/AM, caffeine, calpain inhibitor I, calpain inhibitor II, leupeptin, N-ethyl maleimide, cyclosporin A, acetyl-leucyl-leucyl-normethional, 3,4-dichloroisocoumarin, diisopropylfluorophosphate, phenylmethylsulfonyl fluoride, tetrodotoxin, nimodipine, verapamil, flunarizine, R56865, forskolin, genistein, herbimycin A, interleukin-6, calyculin A, okadaic acid, calyculin A, phorbol-12-myristate-13-acetate, 1-Pyrrolidinecarbodithioic acid, nifedipine, nisoldipine, aurintricarboxylic acid, spermine, thioredoxin, N.sup..alpha. -Tosyl-L-Phe chloromethyl ketone and N.sup..alpha. -Tosyl-L-Lys chloromethyl ketone. 38. The method of claim 37, wherein said apoptosis inhibitor is N-Acetyl-L-cysteine. 39. The method of claim 34, wherein said cell culture comprising porcine primordial germ cells contains undifferentiated cultured cells from an undifferentiated porcine primordial germ cell-derived cell line. 40. The method of claim 34, wherein said transgenic pig is generated by a method comprising: (a) injecting said undifferentiated porcine primordial germ cells that contain said selected DNA segment into a blastocyst from a pig; (b) transferring said blastocyst into a synchronized recipient female pig to produce a pregnant pig; and (c) allowing gestation in said pregnant pig to proceed for a period of time sufficient to allow the development of a viable transgenic pig. 41. The method of claim 34, wherein said transgenic pig is generated by a method comprising: (a) isolating a nucleus from said undifferentiated porcine primordial germ cells that contain said selected DNA segment and injecting said nucleus into an enucleated oocyte from a pig; (b) transferring said oocyte into a synchronized recipient female pig to produce a pregnant pig; and (c) allowing gestation in said pregnant pig to proceed for a period of time sufficient to allow the development of a viable transgenic pig. 42. The method of claim 34, wherein said transgenic pig is generated by a method comprising: (a) aggregating said undifferentiated porcine primordial germ cells that contain said selected DNA segment with an early stage embryo of a pig; (b) transferring said embryo into a synchronized recipient female pig to produce a pregnant pig; and (c) allowing gestation in said pregnant pig to proceed for a period of time sufficient to allow the development of a viable transgenic pig. 43. The method of claim 34, wherein said selected DNA segment comprises at least a first coding region that encodes a protein selected from the group consisting of an interleukin, collagen, interferon, blood protein, hormone, growth factor, cytokine, enzyme, receptor, binding protein, immune system protein, antigen, muscle protein and an oncogene receptor. 44. The method of claim 43, wherein said selected DNA segment comprises at least a first coding region that encodes a protein selected from the group consisting of SREHP, GP63, actinobacillus, pleuropneumoniae, pseudomonas aeruynosa, OprF, myelin basic protein, insulin, hCD59, DAF (CD55), factor IX, urokinase, .alpha.-antitrypsin, tissue plasminogen activator, protein C, activin, adenosine deaminase, angiotensinogen I, antithrombin III, alpha I antitrypsin, apolipoprotein A-I, apolipoprotein A-II, apolipoprotein C-I, apolipoprotein C-II, apolipoprotein C-III, apolipoprotein E, atrial natriuretic factor, chorionic gonadotropin, alpha chain, beta chain, pro (rennin) chymosin, factor B complement, complement C2, complement C3, complement C4, complement C9, corticotropin releasing factor, epidermal growth factor, c-erb B, epoxide dehydratase, erythropoietin, C1 esterase inhibitor, factor VIII, factor IX, Christmas factor, factor X, fibrinogen A alpha, gamma B beta, gastrin releasing peptide, prepro glucagon, growth hormone, RF growth hormone, somatocrinin, hemopexin, inhibin, prepro insulin, insulin-like growth factor I, insulin-like growth factor II, alpha interferon, multiple leukocyte, fibroblast beta interferon, gamma interferon, interleukin-1, T-cell interleukin-2, growth factor, interleukin-3, two forms kininogen, beta subunit leuteinizing hormone, leuteinizing hormone, releasing hormone, lymphotoxin, mast cell growth factor, beta subunit nerve growth factor, PGDF c-sis oncogene, chain A, pancreatic polypeptide, icosapeptide, parathyroid hormone, prepro plasminogen, plasminogen activator, prolactin, proopiomelanocortin, protein C, prothrombin, relaxin, prepro renin, somatostatin, prepro tachykinin, substance P, substance K, urokinase and prepro vasoactive intestinal peptide protein. 45. A method of preparing a porcine blastocyst that contains a selected DNA segment, comprising: (a) introducing said selected DNA segment into a cell culture comprising porcine primordial germ cells to obtain candidate porcine primordial germ cells that contain said selected DNA segment; (b) plating said candidate porcine primordial germ cells that contain said selected DNA segment on feeder cells, said feeder cells at a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 an about 10.sup.6 cells/cm.sup.2, in a culture medium comprising an effective amount of basic fibroblast growth factor and an apoptosis inhibitor, to obtain undifferentiated porcine primordial germ cells that contain said selected DNA segment; and (c) injecting said undifferentiated porcine primordial germ cells that contain said selected DNA segment into a porcine blastocyst, thereby preparing a porcine blastocyst that contains said selected DNA segment. 46. A method of preparing a porcine oocyte that contains a selected DNA segment comprising: (a) introducing said selected DNA segment into a cell culture comprising porcine primordial germ cells to obtain candidate porcine primordial germ cells that contain said selected DNA segment; (b) plating said candidate porcine primordial germ cells that contain said selected DNA segment on feeder cells, said feeder cells at a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 cells/cm.sup.2, in a culture medium comprising an effective of basic fibroblast growth factor and an apoptosis inhibitor, to obtain undifferentiated porcine primordial germ cells that contain said selected DNA segment; (c) isolating a nucleus from said undifferentiated porcine primordial germ cells that contain said selected DNA segment; and (d) injecting said nucleus into an enucleated porcine oocyte, thereby preparing a porcine oocyte that contains said selected DNA segment. 47. (Amended) A method of preparing an early stage porcine embryo that contains a selected DNA segment, comprising: (a) introducing a selected DNA segment into a cell culture comprising porcine primordial germ cells to obtain candidate porcine primordial germ cells that contain said selected. DNA segment; (b) plating said candidate porcine primordial germ cells that contain said selected DNA segment on feeder cells, said feeder cells at a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 cells/cm.sup.2, in a culture medium comprising an effective amount of basic fibroblast growth factor and an apoptosis inhibitor, to obtain undifferentiated porcine primordial germ cells that contain said selected DNA segment; and (c) aggregating said undifferentiated porcine primordial germ cells that contain said selected DNA segment with an early stage porcine embryo, thereby preparing an early stage porcine embryo that contains said selected DNA segment. 48. A cell culture comprising: (a) porcine primordial germ cells; (b) feeder cells sufficient to achieve a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 feeder cells/cm.sup.2 ; and (c) an mount of basic fibroblast growth factor and an apoptosis inhibitor effective to promote the growth and continued proliferation of said porcine primordial germ cells. 49. The cell culture of claim 48, wherein said apoptosis inhibitor is a serine protease apoptosis inhibitor. 50. The cell culture of claim 48, wherein said apoptosis inhibitor is an antioxidant apoptosis inhibitor. 51. The cell culture of claim 48, wherein said apoptosis inhibitor is selected from the group consisting of bcl-2, Bcl-x1, Mcl-1, Bak, A1, A20, TNF-.alpha., nerve growth factor, epidermal growth factor, insulin-like growth factor-I, insulin-like growth factor-I receptor, 3-aminobenzamide, aphidocolin, L-ascorbic acid, catalase, follicle stimulating hormone, vasoactive intestinal peptide, cyclic GMP, hCG, interleukin-1.beta., superoxide dismutase, aurintricarboxylic acid, BAPTA/AM, caffeine, calpain inhibitor I, calpain inhibitor II, leupeptin, N-ethyl maleimide, cyclosporin A, acetyl-leucyl-leucyl-normethional, 3,4-dichloroisocoumarin, diisopropylfluorophosphate, phenylmethylsulfonyl fluoride, tetrodotoxin, nimodipine, verapamil, flunarizine, R56865, forskolin, genistein, herbimycin A, interleukin-6, calyculin A, okadaic acid, calyculin A, phorbol-12-myristate-13-acetate, 1-Pyrrolidinecarbodithioic acid, nifedipine, nisoldipine, aurintricarboxylic acid, spermine, thioredoxin, N.sup..alpha. -Tosyl-L-Phe chloromethyl ketone and N.sup..alpha. -Tosyl-L-Lys chloromethyl ketone. 52. The cell culture of claim 51, wherein said apoptosis inhibitor is N-Acetyl-L-cysteine. 53. The cell culture of claim 48, wherein said porcine primordial germ cells comprise at least a first exogenous DNA segment. 54. A kit comprising, in suitable container means: (a) porcine primordial germ cells; (b) feeder cells sufficient to achieve a density of between about 2.5.times.10.sup.5 cells/cm.sup.2 and about 10.sup.6 feeder cells/cm.sup.2 ; and (c) an amount of basic fibroblast growth factor and an apoptosis inhibitor effective to promote the growth and continued proliferation of said porcine primordial germ cells. 55. The kit of claim 54, wherein said apoptosis inhibitor is a serine protease apoptosis inhibitor. 56. The kit of claim 54, wherein said apoptosis inhibitor is an antioxidant apoptosis inhibitor. 57. The kit of claim 54, wherein said apoptosis inhibitor is selected from the group consisting of bcl-2, Bcl-x1, Mcl-1, Bak, A1, A20, TNF-A, nerve growth factor, epidermal growth factor, insulin-like growth factor-I, insulin-like growth factor-I receptor, 3-aminobenzamide, aphidocolin, L-ascorbic acid, catalase, follicle stimulating hormone, vasoactive intestinal peptide, cyclic GMP, hCG, interleukin-1.beta.,superoxide dismutase, aurintricarboxylic acid, BAPTA/AM, caffeine, calpain inhibitor I, calpain inhibitor II, leupeptin, N-ethyl maleimide, cyclosporin A, acetyl-leucyl-leucyl-normethional, 3,4-dichloroisocoumarin, diisopropylfluorophosphate, phenylmethylsulfonyl fluoride, tetrodotoxin, nimodipine, verapamil, flunarizine, R56865, forskolin, genistein, herbimycin A, interleukin-6, calyculin A, okadaic acid, calyculin A, phorbol-12-myristate-13-acetate, 1-Pyrrolidinecarbodithioic acid, nifedipine, nisoldipine, aurintricarboxylic acid, spermine, thioredoxin, N.sup..alpha. -Tosyl-L-Phe chloromethyl ketone and N.sup..alpha. -Tosyl-L-Lys chloromethyl ketone. 58. The kit of claim 57, wherein said apoptosis inhibitor is N-Acetyl-L-cysteine.

Details for Patent 6,369,294

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2016-10-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2016-10-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2016-10-01
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2016-10-01